...
首页> 外文期刊>Acta Neuropathologica >Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma
【24h】

Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma

机译:结合分子分析的BRAF和IDH1区分毛细胞星形细胞瘤和弥漫性星形细胞瘤

获取原文
获取原文并翻译 | 示例
           

摘要

Separation of pilocytic astrocytoma from diffuse astrocytomas frequently poses problems mostly related to small sample size. Precise classification and grading are essential due to different therapeutic strategies prompted by diagnoses of pilocytic astrocytoma WHO grade I, diffuse astrocytomas WHO grade II or anaplastic astrocytoma WHO grade III. Recently, genomic aberrations with a high specificity for distinct glioma entities have been described. Pilocytic astrocytomas carry a duplication at chromosome band 7q34 containing a BRAF–KIAA1549 gene fusion in the majority of cases. IDH1 mutations are observed very frequently in adult astrocytomas and IDH2 mutations have been reported in some astrocytomas. We examined a series of 120 astrocytomas including 70 pilocytic astrocytomas WHO grade I and 50 diffuse astrocytomas WHO grade II for both, BRAF–KIAA1549 fusion with a newly developed FISH assay and mutations in IDH1 and IDH2 by direct sequencing. Pilocytic astrocytomas contained the BRAF fusion in 49 cases (70%) but neither IDH1 nor IDH2 mutations. Astrocytomas WHO grade II exhibited IDH1 mutations in 38 cases (76%) but neither IDH2 mutations nor BRAF fusions. Thus, combined molecular analysis of BRAF and IDH1 is a sensitive and highly specific approach to separate pilocytic astrocytoma from diffuse astrocytoma. Keywords BRAF - IDH1 - IDH2 - Pilocytic astrocytoma - Diffuse astrocytoma
机译:淋巴细胞性星形细胞瘤与弥漫性星形细胞瘤的分离通常会带来一些问题,这些问题主要与样本量小有关。由于诊断蜂窝细胞性星形细胞瘤WHO等级I,弥漫性星形细胞瘤WHO等级II或间变性星形细胞瘤WHO等级III所提示的治疗策略的不同,精确的分类和分级至关重要。最近,已经描述了对不同神经胶质瘤实体具有高特异性的基因组畸变。在大多数情况下,上叶星形细胞瘤在染色体7q34处有一个重复,其中包含BRAF–KIAA1549基因融合。 IDH1突变在成人星形细胞瘤中非常常见,而IDH2突变在某些星形细胞瘤中已有报道。我们检查了一系列120种星形细胞瘤,包括70种I级毛细血管星形细胞瘤和50种II级弥漫性星形细胞瘤,BRAF–KIAA1549与新开发的FISH检测融合以及IDH1和IDH2直接测序的突变。上皮星形细胞瘤包含BRAF融合49例(70%),但没有IDH1和IDH2突变。世卫组织II级星形细胞瘤显示38例(76%)IDH1突变,但IDH2突变和BRAF融合均无。因此,BRAF和IDH1的联合分子分析是区分弥漫性星形细胞瘤的细胞性星形细胞瘤的灵敏且高度特异性的方法。关键词BRAF-IDH1-IDH2-多发性星形细胞瘤-弥漫性星形细胞瘤

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号